In 521 patients with untreated PD-L1-high advanced NSCLC, adding tiragolumab to atezolizumab did not significantly improve PFS (median 7.0 vs 5.6 months; HR 0.78, nonsignificant) or OS (23.1 vs 16.9 months; HR 0.87, P=.22); grade 3-4 adverse events 41.2% vs 33.8%.
RCTn = 521
Peters et al. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer